Several pharmaceutical and biotech stocks surged in premarket trading Monday as investors reacted to a hantavirus outbreak, with Moderna Inc. shares climbing 7% after confirming preclinical research on the virus.
"Moderna has conducted preclinical research on Hantaviruses in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), reflecting the ongoing regional impact of these pathogens," the company said in a statement.
The rally also saw shares of Inovio Pharmaceuticals jump 11%, while Novavax rose 5%. The moves follow a World Health Organization report on May 2 flagging an outbreak of the Andes virus strain of hantavirus, a respiratory disease spread by rodents, on a cruise ship. The WHO has reported eight cases and three deaths so far, but maintains the overall public health risk is low.
Despite the low risk, the outbreak drives speculative investment into firms with vaccine development platforms. Evercore ISI analysts noted that for Moderna, "we see no meaningful revenue opportunity," viewing the stock's move as "sentiment-driven, not fundamental," while reinforcing the agility of its mRNA platform post-COVID.
The WHO has confirmed that the Andes virus is the only hantavirus species known to be transmissible between humans, though such instances are rare. The focus for investors now shifts to how quickly these companies can adapt their vaccine technologies. This event highlights the market's sensitivity to new infectious disease threats and the speculative premium placed on platform companies like Moderna, even when the immediate commercial path is unclear.
This article is for informational purposes only and does not constitute investment advice.
